retatrutide type 2 diabetes trial results Eli Lilly just announced striking Phase 3 for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide is gaining attention in

The question is whether quad-receptor engagement crosses a complexity threshold where the affinity-ratio engineering becomes infeasible

Influence of Feeding Schedules on the Chronobiology of Renin Activity, Urinary Electrolytes and Blood Pressure in Dogs

Q3: How does CoverWell protect patients

First-time AOM semaglutide prescribing increased by over 50%, marking the largest quarter-over-quarter increase in first-time AOM semaglutide prescribing since mid-2024, likely driven by the approval of the oral formulation of Wegovy in December 2025

The high demand for effective weight loss treatments, coupled with increasing awareness of Semaglutide's benefits, contributed to its market leadership, despite the presence of other GLP-1 drugs